Express Scripts Sues FTC Over Drug Pricing Report

FTC's Report Alleges Express Scripts Inflated Drug Prices

Express Scripts, a pharmacy benefit manager (PBM), is suing the Federal Trade Commission (FTC) over a report that alleges the company inflated drug prices. The FTC's report, released in December 2022, found that Express Scripts used its market power to negotiate higher prices for drugs from pharmaceutical companies. The report also alleged that Express Scripts used its rebates and discounts to steer patients to more expensive drugs, even when cheaper alternatives were available.

Express Scripts Denies Wrongdoing

Express Scripts has denied the FTC's allegations, arguing that the report is based on "flawed data and analysis." The company says that it has always acted in the best interests of its customers and that it has never inflated drug prices.

FTC's Lawsuit Seeks to Block Express Scripts' Practices

The FTC's lawsuit seeks to block Express Scripts from continuing its alleged practices. The lawsuit also seeks to force Express Scripts to refund any overcharges to consumers. The FTC's lawsuit is a significant development in the ongoing debate over drug pricing in the United States. If the FTC is successful in its lawsuit, it could lead to lower drug prices for consumers.

Express Scripts' Lawsuit is a Counterattack

Express Scripts' lawsuit is a counterattack against the FTC's report. The company is arguing that the FTC's report is biased and that the FTC is overstepping its authority. Express Scripts is also arguing that the FTC's lawsuit will harm consumers by making it more difficult for them to access affordable drugs.

The Outcome of the Lawsuit is Uncertain

The outcome of the lawsuit is uncertain. The FTC has a strong case against Express Scripts, but the company is a powerful player in the drug industry. The lawsuit is likely to drag on for several years, and it is possible that it could end up in the Supreme Court.